Literature DB >> 15097884

Retinal features predictive of progressive stage 4 retinopathy of prematurity.

M Elizabeth Hartnett1, Janet R McColm.   

Abstract

PURPOSE: To determine the retinal features predictive of progressive stage 4 retinopathy of prematurity (ROP) after laser treatment for threshold ROP.
METHODS: Retrospective review of 72 eyes of 37 infants after laser treatment for threshold ROP between 1993 and 2002. Retinal features were abstracted from examinations made within 1 week of development of stage 4A ROP or 2 weeks after laser treatment in eyes with regressed threshold disease. Predictive features of progressive stage 4 ROP were determined using a generalized estimating equation model to account for within-subject variability.
RESULTS: The generalized estimating equation showed that vitreous state, ridge elevation of six or more clock hours, and two or more quadrants of plus disease predicted progressive retinal detachment, whereas two or more quadrants of neovascularization did not.
CONCLUSIONS: Progressive stage 4 ROP requiring surgical intervention was predicted by the absence of clear vitreous, ridge elevation of six or more clock hours, and two or more quadrants of plus disease, but not by neovascularization. These results may be useful in the management of eyes after laser treatment for threshold ROP.

Entities:  

Mesh:

Year:  2004        PMID: 15097884      PMCID: PMC1828043          DOI: 10.1097/00006982-200404000-00008

Source DB:  PubMed          Journal:  Retina        ISSN: 0275-004X            Impact factor:   4.256


  19 in total

1.  Supplemental Therapeutic Oxygen for Prethreshold Retinopathy Of Prematurity (STOP-ROP), a randomized, controlled trial. I: primary outcomes.

Authors: 
Journal:  Pediatrics       Date:  2000-02       Impact factor: 7.124

2.  Long-term vision results measured with Teller Acuity Cards and a new Light Perception/Projection Scale after management of late stages of retinopathy of prematurity.

Authors:  M Elizabeth Hartnett; Dorothy W Rodier; Janet R McColm; Hilary W Thompson
Journal:  Arch Ophthalmol       Date:  2003-07

3.  Lens-sparing vitreous surgery for tractional stage 4A retinopathy of prematurity retinal detachments.

Authors:  A Capone; M T Trese
Journal:  Ophthalmology       Date:  2001-11       Impact factor: 12.079

4.  An international classification of retinopathy of prematurity. The Committee for the Classification of Retinopathy of Prematurity.

Authors: 
Journal:  Arch Ophthalmol       Date:  1984-08

5.  A comparison of laser photocoagulation with cryotherapy for threshold retinopathy of prematurity at 10 years: part 1. Visual function and structural outcome.

Authors:  Eugene Y J Ng; Brian P Connolly; J Arch McNamara; Carl D Regillo; James F Vander; William Tasman
Journal:  Ophthalmology       Date:  2002-05       Impact factor: 12.079

6.  Reduced severity of oxygen-induced retinopathy in eNOS-deficient mice.

Authors:  S E Brooks; X Gu; S Samuel; D M Marcus; M Bartoli; P L Huang; R B Caldwell
Journal:  Invest Ophthalmol Vis Sci       Date:  2001-01       Impact factor: 4.799

7.  Vascular endothelial growth factor and hepatocyte growth factor levels are differentially elevated in patients with advanced retinopathy of prematurity.

Authors:  K Lashkari; T Hirose; J Yazdany; J W McMeel; A Kazlauskas; N Rahimi
Journal:  Am J Pathol       Date:  2000-04       Impact factor: 4.307

8.  Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid.

Authors:  D R Senger; S J Galli; A M Dvorak; C A Perruzzi; V S Harvey; H F Dvorak
Journal:  Science       Date:  1983-02-25       Impact factor: 47.728

9.  Correlation of retinopathy of prematurity in fellow eyes in the cryotherapy for retinopathy of prematurity study. The Cryotherapy for Retinopathy of Prematurity Cooperative Group.

Authors:  G E Quinn; V Dobson; A Biglan; J Evans; D Plotsky; R J Hardy
Journal:  Arch Ophthalmol       Date:  1995-04

10.  Visual results of lens-sparing vitreoretinal surgery in infants.

Authors:  A M Maguire; M T Trese
Journal:  J Pediatr Ophthalmol Strabismus       Date:  1993 Jan-Feb       Impact factor: 1.402

View more
  9 in total

1.  Fibrovascular organization in the vitreous following laser for ROP: implications for prognosis.

Authors:  M Elizabeth Hartnett; Janet R McColm
Journal:  Retina       Date:  2006-09       Impact factor: 4.256

2.  Treatment for stage 4A retinopathy of prematurity: laser and/or ranibizumab.

Authors:  Emine Alyamaç Sukgen; Yusuf Koçluk
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2016-08-06       Impact factor: 3.117

3.  Retinopathy of prematurity: involution, factors predisposing to retinal detachment, and expected utility of preemptive surgical reintervention.

Authors:  David K Coats
Journal:  Trans Am Ophthalmol Soc       Date:  2005

Review 4.  Advances in understanding and management of retinopathy of prematurity.

Authors:  Mary Elizabeth Hartnett
Journal:  Surv Ophthalmol       Date:  2016-12-22       Impact factor: 6.048

Review 5.  Vascular endothelial growth factor antagonist therapy for retinopathy of prematurity.

Authors:  M Elizabeth Hartnett
Journal:  Clin Perinatol       Date:  2014-09-23       Impact factor: 3.430

Review 6.  Studies on the pathogenesis of avascular retina and neovascularization into the vitreous in peripheral severe retinopathy of prematurity (an american ophthalmological society thesis).

Authors:  Mary Elizabeth Hartnett
Journal:  Trans Am Ophthalmol Soc       Date:  2010-12

7.  A review of treatment for retinopathy of prematurity.

Authors:  Eric D Hansen; M Elizabeth Hartnett
Journal:  Expert Rev Ophthalmol       Date:  2019-03-29

8.  Retinopathy of prematurity: a review of epidemiology and current treatment strategies.

Authors:  Eun Hee Hong; Yong Un Shin; Heeyoon Cho
Journal:  Clin Exp Pediatr       Date:  2021-10-12

9.  Variation in the vitreoretinal configuration of Stage 4 retinopathy of prematurity in photocoagulated and treatment naive eyes undergoing vitrectomy.

Authors:  Salil Sharad Gadkari; Madan Deshpande
Journal:  Indian J Ophthalmol       Date:  2017-09       Impact factor: 1.848

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.